// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //

VANCOUVER, BC, Dec. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 2,200,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000.

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //

VANCOUVER, BC, Dec. 13, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 2,200,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000.

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //

VANCOUVER, BC, Dec. 11, 2024 /CNW/ --  BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has reduced the price per unit of the Company ("Unit") in connection with the non-brokered private placement offering (the "Offering") previously announced on November 18, 2024, and has also increased the number of Units offered.

The price per Unit has been reduced from $0.07 per Unit to $0.05 per Unit. As the Company's intention to raise $1,000,000 remains unchanged, the number of Units offered has increased from 14,285,715 Units to 20,000,000 Units accordingly.

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES //

VANCOUVER, BC, Dec. 11, 2024 /PRNewswire/ --  BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has reduced the price per unit of the Company ("Unit") in connection with the non-brokered private placement offering (the "Offering") previously announced on November 18, 2024, and has also increased the number of Units offered.

The price per Unit has been reduced from $0.07 per Unit to $0.05 per Unit. As the Company's intention to raise $1,000,000 remains unchanged, the number of Units offered has increased from 14,285,715 Units to 20,000,000 Units accordingly.

DPX Formulations Superior to Mixing with Commonly Used Adjuvants

DPX Without Antigen Cargo Has Immune Stimulating Properties

Unique Potential for DPX in New Fields of Use

VANCOUVER, BC, Dec. 5, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) in Boston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP antigen delivery systems. The study demonstrates that DPX formulations with tumor-derived peptide neoantigens are highly effective vaccines to inhibit or prevent tumor growth following tumor challenges. DPX formulations were more effective than mixing with commonly used adjuvants, and DPX formulations were demonstrated to be as effective as the gold standard, bone marrow-derived dendritic cells. A highly significant result of the study is DPX formulations (with a checkpoint inhibitor) without a packaged cargo peptide appear to have meaningful immune stimulating properties on their own.

DPX Formulations Superior to Mixing with Commonly Used Adjuvants

DPX Without Antigen Cargo Has Immune Stimulating Properties

Unique Potential for DPX in New Fields of Use

VANCOUVER, BC, Dec. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) in Boston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP antigen delivery systems. The study demonstrates that DPX formulations with tumor-derived peptide neoantigens are highly effective vaccines to inhibit or prevent tumor growth following tumor challenges. DPX formulations were more effective than mixing with commonly used adjuvants, and DPX formulations were demonstrated to be as effective as the gold standard, bone marrow-derived dendritic cells. A highly significant result of the study is DPX formulations (with a checkpoint inhibitor) without a packaged cargo peptide appear to have meaningful immune stimulating properties on their own.

VANCOUVER, BC, Nov. 5, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.

VANCOUVER, BC, Nov. 5, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.

Die Ergebnisse der Studie positionieren das Unternehmen als Zielgruppe für Segmente des über 270 Mrd. USD schweren Marktes für Arzneimittelverabreichungssysteme 1 

VANCOUVER, BC, 31. Oktober 2024 /PRNewswire/ – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen") hebt Studien hervor, die zeigen, dass seine neuartige immunbildende Verabreichungsplattform DPX™ einzigartige Untergruppen von Antigen-präsentierenden Zellen („APCs") rekrutiert und aktiviert, um die Immunogenität von Antigenen voranzutreiben, und im Vergleich zu wässrigen und emulsionsbasierten Antigenverabreichungssystemen eine bessere Immunaktivierung aufweist.

Study Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market1

VANCOUVER, BC, Oct. 31, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights studies showing that its novel immune educating delivery platform, DPX™, recruits and activates unique subsets of antigen presenting cells ("APCs") to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems.